KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Accured Expenses: 2022-2024

Historic Change in Accured Expenses for AbCellera Biologics (ABCL) over the last 3 years, with Dec 2024 value amounting to $10.6 million.

  • AbCellera Biologics' Change in Accured Expenses rose 22.23% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year change of. This contributed to the annual value of $10.6 million for FY2024, which is 170.41% up from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Change in Accured Expenses is $10.6 million, which was up 170.41% from -$15.1 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Change in Accured Expenses registered a high of $10.6 million during FY2024, and its lowest value of -$15.1 million during FY2023.
  • In the last 3 years, AbCellera Biologics' Change in Accured Expenses had a median value of -$2.1 million in 2022 and averaged -$2.2 million.
  • As far as peak fluctuations go, AbCellera Biologics' Change in Accured Expenses crashed by 621.30% in 2023, and later skyrocketed by 170.41% in 2024.
  • Over the past 3 years, AbCellera Biologics' Change in Accured Expenses (Yearly) stood at -$2.1 million in 2022, then plummeted by 621.30% to -$15.1 million in 2023, then surged by 170.41% to $10.6 million in 2024.